miglustat has been researched along with Diarrhea in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gianutsos, J; Kolodny, EH; Luzy, C; Pastores, GM; Shapiro, BE | 1 |
Banwell, B; Clarke, JT; Dingemanse, J; Maegawa, GH; Morgan, CP; Tifft, CJ; van Giersbergen, PL; Yang, S | 1 |
Abel, L; Chadha-Boreham, H; Giorgino, R; Jacklin, E; Luzy, C; Patterson, MC; Vecchio, D; Wraith, JE | 1 |
Aspinall, RL; Collier, AC; Coombs, R; Fass, RJ; Fife, KH; Fischl, MA; Kremer, AB; Pottage, JC; Powderly, WG; Resnick, L | 1 |
Fischl, M; Karim, A; Kessler, H; Merigan, T; Pottage, J; Powderly, W; Richman, D; Sherman, J; Smith, S; Tierney, M | 1 |
Aerts, J; Butters, T; Cox, T; Dwek, R; Elstein, D; Gow, I; Hollak, C; HrebĂcek, M; Lachmann, R; Moyses, C; Platt, F; van Weely, S; Zimran, A | 1 |
6 trial(s) available for miglustat and Diarrhea
Article | Year |
---|---|
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Age of Onset; Diarrhea; Enzyme Inhibitors; Fatigue; Female; Glycoside Hydrolase Inhibitors; Humans; Male; Middle Aged; Tay-Sachs Disease; Time Factors; Treatment Outcome; Weight Loss; Young Adult | 2009 |
Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.
Topics: 1-Deoxynojirimycin; Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Gangliosidoses, GM2; Glucosyltransferases; Humans; Infant | 2009 |
Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Child; Deglutition; Diarrhea; Female; Humans; Niemann-Pick Disease, Type C; Walking; Weight Loss | 2010 |
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
Topics: 1-Deoxynojirimycin; Adult; Antiviral Agents; beta 2-Microglobulin; CD4-Positive T-Lymphocytes; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocyte Count; Male; Neutrophils; Paresthesia; RNA, Viral; Zidovudine | 1994 |
The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases.
Topics: 1-Deoxynojirimycin; Adult; Animals; Antiviral Agents; Cataract; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Diarrhea; Female; Flatulence; Half-Life; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lens, Crystalline; Leukopenia; Liver; Male; Neutropenia; Rats | 1995 |
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
Topics: 1-Deoxynojirimycin; Administration, Oral; Adult; Aged; Diarrhea; Enzyme Inhibitors; Female; Gaucher Disease; Glucosyltransferases; Half-Life; Hexosaminidases; Humans; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Spleen; Tomography, X-Ray Computed | 2000 |